Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Samotolisib · LY-3023414

Small molecule · Inhibitor of PI3K (PIK3CA), mTOR and DNA-PK (PRKDC) · developed by Eli Lilly and Company

Phase 2 Most advanced trial
1 Registered trials

What is Samotolisib?

Samotolisib (LY3023414) is an orally bioavailable small molecule inhibitor of class I PI3K isoforms, mTOR, and DNA-PK. It inhibits the PI3K/mTOR signaling pathway and DNA repair mechanisms in tumor cells. The drug is studied in endometrial cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
LY-3023414
Drug type
Small molecule
Targets
PI3K (PIK3CA), mTOR, DNA-PK (PRKDC)
Mechanism
Inhibitor of PI3K (PIK3CA), mTOR and DNA-PK (PRKDC)
Pathways
PI3K/mTOR signaling, DNA repair
Therapy area
Oncology
Developer
Eli Lilly and Company
In trials of
CELC
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
C88817F47Y

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03675893 Phase 2 Endometrial Cancer Recruiting CELC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Endometrial Cancer

Other drugs acting on PIK3CA / MTOR / PRKDC

Gedatolisib FDA approved Sirolimus FDA approved CC-115 Phase 2 CERC-006 Phase 1 CGT6297 Phase 1 Encapsulated Rapamycin Phase 2 Serabelisib Phase 2 Tersolisib Phase 3

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.